Additionally, expression levels of this NAT are increased in the brains of AD patients and in amyloid precursor protein (APP) transgenic mice indicating that BACE1-AS levels can serve both as a candidate diagnostic marker and therapeutic target for AD [84]. The gene discussed is UBE3A; the disease is Alzheimer disease.